{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:48:53Z","timestamp":1794473333515,"version":"4.9.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007465","name":"UiT The Arctic University of Norway","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007465","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Established prognostic models, such as the diagnosis-specific graded prognostic assessment, were not designed to specifically address very short survival. Therefore, a brain metastases-specific 30-day mortality model may be relevant. We hypothesized that in-depth evaluation of a carefully defined cohort with short survival, arbitrarily defined as a maximum of 3\u00a0months, may provide signals and insights, which facilitate the development of a 30-day mortality model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective analysis (2011\u20132021) of patients treated for brain metastases with different approaches. Risk factors for 30-day mortality from radiosurgery or other primary treatment were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The cause of death was unrelated to brain metastases in 61%. Treatment-related death (grade 5 toxicity) did not occur. Completely unexpected death was not observed, e.g. accident, suicide or sudden cardiac death. Logistic regression analysis showed 9 factors associated with 30-day mortality (each assigned 3\u20136 points) and a point sum was calculated for each patient. The point sum ranged from 0 (no risk factors for death within 30\u00a0days present) to 30. The results can be grouped into 3 or 4 risk categories. Eighty-three percent of patients in the highest risk group (&gt;\u200916\u00a0points) died within 30\u00a0days, and none survived for more than 2\u00a0months. However, many cases of 30-day mortality (more than half) occurred in intermediate risk categories.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Extracranial tumor progression was the prevailing cause of 30-day mortality and few, if any deaths could be considered relatively unexpected when looking at the complete oncological picture. We were able to develop a multifactorial prediction model. However, the model\u2019s performance was not fully satisfactory and it is not routinely applicable at this point in time, because external validation is needed to confirm our hypothesis-generating findings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-022-02062-x","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T11:04:04Z","timestamp":1652353444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["30-day mortality in patients treated for brain metastases: extracranial causes dominate"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1592-2908","authenticated-orcid":false,"given":"Carsten","family":"Nieder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"Stanisavljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siv Gyda","family":"Aanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e5rd","family":"Manns\u00e5ker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellinor Christin","family":"Haukland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"2062_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.hoc.2021.08.004","volume":"36","author":"E Nieblas-Bedolla","year":"2022","unstructured":"Nieblas-Bedolla E, Zuccato J, Kluger H, Zadeh G, Brastianos PK. Central nervous system metastases. Hematol Oncol Clin North Am. 2022;36:161\u201388. https:\/\/doi.org\/10.1016\/j.hoc.2021.08.004.","journal-title":"Hematol Oncol Clin North Am"},{"key":"2062_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.rpor.2020.03.001","volume":"25","author":"C Nieder","year":"2020","unstructured":"Nieder C, Hintz M, Popp I, Bilger A, Grosu AL. Long-term survival results after treatment for oligometastatic brain disease. Rep Pract Oncol Radiother. 2020;25:307\u201311. https:\/\/doi.org\/10.1016\/j.rpor.2020.03.001.","journal-title":"Rep Pract Oncol Radiother"},{"key":"2062_CR3","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1200\/JCO.20.01255","volume":"38","author":"PW Sperduto","year":"2020","unstructured":"Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, et al. Survival in patients with brain metastases: Summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol. 2020;38:3773\u201384. https:\/\/doi.org\/10.1200\/JCO.20.01255.","journal-title":"J Clin Oncol"},{"key":"2062_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2018.03.018","volume":"126","author":"C Nieder","year":"2018","unstructured":"Nieder C, Mehta MP, Geinitz H, Grosu AL. Prognostic and predictive factors in patients with brain metastases from solid tumors: a review of published nomograms. Crit Rev Oncol Hematol. 2018;126:13\u20138. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.03.018.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2062_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13014-020-01558-8.Erratum.In:RadiatOncol.2020;15:280","volume":"15","author":"J Schaule","year":"2020","unstructured":"Schaule J, Kroeze SGC, Blanck O, Stera S, Kahl KH, Roeder F, et al. Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy: melanoma brain metastases prognostic score. Radiat Oncol. 2020;15:135. https:\/\/doi.org\/10.1186\/s13014-020-01558-8.Erratum.In:RadiatOncol.2020;15:280.","journal-title":"Radiat Oncol"},{"key":"2062_CR6","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(16)30825-X","volume":"388","author":"P Mulvenna","year":"2016","unstructured":"Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388:2004\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(16)30825-X.","journal-title":"Lancet"},{"key":"2062_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/PPO.0000000000000459","volume":"26","author":"EK Seymour","year":"2020","unstructured":"Seymour EK, de Souza JA, Fendrick AM. Incorporating value-based care into oncology. Cancer J. 2020;26:311\u201322. https:\/\/doi.org\/10.1097\/PPO.0000000000000459.","journal-title":"Cancer J"},{"key":"2062_CR8","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41416-021-01495-7","volume":"125","author":"JB Schnog","year":"2021","unstructured":"Schnog JB, Samson MJ, Gans ROB, Duits AJ. An urgent call to raise the bar in oncology. Br J Cancer. 2021;125:1477\u201385. https:\/\/doi.org\/10.1038\/s41416-021-01495-7.","journal-title":"Br J Cancer"},{"key":"2062_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.lungcan.2019.12.015","volume":"141","author":"GS Jones","year":"2020","unstructured":"Jones GS, Elimian K, Baldwin DR, Hubbard RB, McKeever TM. A systematic review of survival following anti-cancer treatment for small cell lung cancer. Lung Cancer. 2020;141:44\u201355. https:\/\/doi.org\/10.1016\/j.lungcan.2019.12.015.","journal-title":"Lung Cancer"},{"key":"2062_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.breast.2017.02.003","volume":"32","author":"TG Yoo","year":"2017","unstructured":"Yoo TG, Cranshaw I, Broom R, Pandanaboyana S, Bartlett A. Systematic review of early and long-term outcome of liver resection for metastatic breast cancer: Is there a survival benefit? Breast. 2017;32:162\u201372. https:\/\/doi.org\/10.1016\/j.breast.2017.02.003.","journal-title":"Breast"},{"key":"2062_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/cncr.28408","volume":"120","author":"MS Krishnan","year":"2014","unstructured":"Krishnan MS, Epstein-Peterson Z, Chen YH, Tseng YD, Wright AA, Temel JS, et al. Predicting life expectancy in patients with metastatic cancer receiving palliative radiotherapy: the TEACHH model. Cancer. 2014;120:134\u201341. https:\/\/doi.org\/10.1002\/cncr.28408.","journal-title":"Cancer"},{"key":"2062_CR12","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.3892\/ol.2015.3656","volume":"10","author":"C Nieder","year":"2015","unstructured":"Nieder C, Angelo K, Dalhaug A, Pawinski A, Haukland E, Norum J. Palliative radiotherapy during the last month of life: predictability for referring physicians and radiation oncologists. Oncol Lett. 2015;10:3043\u20139. https:\/\/doi.org\/10.3892\/ol.2015.3656.","journal-title":"Oncol Lett"},{"key":"2062_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.clon.2008.03.005","volume":"20","author":"C Nieder","year":"2008","unstructured":"Nieder C, Marienhagen K, Thamm R, Astner ST, Molls M, Norum J. Prediction of very short survival in patients with brain metastases from breast cancer. Clin Oncol (R Coll Radiol). 2008;20:337\u20139. https:\/\/doi.org\/10.1016\/j.clon.2008.03.005.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2062_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/COC.0000000000000784","volume":"44","author":"C Nieder","year":"2021","unstructured":"Nieder C, Yobuta R, Manns\u00e5ker B. Expansion of the LabBM score: is the LabPS the best tool predicting survival in patients with brain metastases? Am J Clin Oncol. 2021;44:53\u20137. https:\/\/doi.org\/10.1097\/COC.0000000000000784.","journal-title":"Am J Clin Oncol"},{"key":"2062_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000506954","volume":"43","author":"C Nieder","year":"2020","unstructured":"Nieder C, Hess S, Lewitzki V. External validation of a prognostic score for patients with brain metastases: extended diagnosis-specific graded prognostic assessment. Oncol Res Treat. 2020;43:221\u20137. https:\/\/doi.org\/10.1159\/000506954.","journal-title":"Oncol Res Treat"},{"key":"2062_CR16","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/neuonc\/now290","volume":"19","author":"AS Berghoff","year":"2017","unstructured":"Berghoff AS, Wolpert F, Holland-Letz T, Koller R, Widhalm G, Gatterbauer B, et al. Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases\u2013development and validation of the LabBM score. Neuro Oncol. 2017;19:1255\u201362. https:\/\/doi.org\/10.1093\/neuonc\/now290.","journal-title":"Neuro Oncol"},{"key":"2062_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.radonc.2021.02.038","volume":"159","author":"C Nieder","year":"2021","unstructured":"Nieder C, Mehta MP, Guckenberger M, Gaspar LE, Rusthoven CG, Sahgal A, et al. Assessment of extracranial metastatic disease in patients with brain metastases: how much effort is needed in the context of evolving survival prediction models? Radiother Oncol. 2021;159:17\u201320. https:\/\/doi.org\/10.1016\/j.radonc.2021.02.038.","journal-title":"Radiother Oncol"},{"key":"2062_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00066-008-1831-5","volume":"184","author":"D Rades","year":"2008","unstructured":"Rades D, Dunst J, Schild SE. A new scoring system to predicting the survival of patients treated with whole-brain radiotherapy for brain metastases. Strahlenther Onkol. 2008;184:251\u20135. https:\/\/doi.org\/10.1007\/s00066-008-1831-5.","journal-title":"Strahlenther Onkol"},{"key":"2062_CR19","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.ijrobp.2010.03.031","volume":"80","author":"D Rades","year":"2011","unstructured":"Rades D, Dziggel L, Haatanen T, Veninga T, Lohynska R, Dunst J, et al. Scoring systems to estimate intracerebral control and survival rates of patients irradiated for brain metastases. Int J Radiat Oncol Biol Phys. 2011;80:1122\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.03.031.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2062_CR20","doi-asserted-by":"publisher","first-page":"5781","DOI":"10.1002\/cam4.3257","volume":"9","author":"AE Mojica-M\u00e1rquez","year":"2020","unstructured":"Mojica-M\u00e1rquez AE, Rodr\u00edguez-L\u00f3pez JL, Patel AK, Ling DC, Rajagopalan MS, Beriwal S. External validation of life expectancy prognostic models in patients evaluated for palliative radiotherapy at the end-of-life. Cancer Med. 2020;9:5781\u20137. https:\/\/doi.org\/10.1002\/cam4.3257.","journal-title":"Cancer Med"},{"key":"2062_CR21","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.21037\/apm.2017.03.04","volume":"6","author":"JJ Ryoo","year":"2017","unstructured":"Ryoo JJ, Batech M, Zheng C, Kim RW, Gould MK, Kagan AR, et al. Radiotherapy for brain metastases near the end of life in an integrated health care system. Ann Palliat Med. 2017;6:S28-38. https:\/\/doi.org\/10.21037\/apm.2017.03.04.","journal-title":"Ann Palliat Med"},{"key":"2062_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.radonc.2017.09.016","volume":"125","author":"KR Park","year":"2017","unstructured":"Park KR, Lee CG, Tseng YD, Liao JJ, Reddy S, Bruera E, et al. Palliative radiation therapy in the last 30 days of life: a systematic review. Radiother Oncol. 2017;125:193\u20139. https:\/\/doi.org\/10.1016\/j.radonc.2017.09.016.","journal-title":"Radiother Oncol"},{"key":"2062_CR23","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/imj.14377","volume":"50","author":"G Pitson","year":"2020","unstructured":"Pitson G, Matheson L, Garrard B, Eastman P, Rogers M. Population-based analysis of radiotherapy and chemotherapy treatment in the last month of life within regional Australia. Intern Med J. 2020;50:596\u2013602. https:\/\/doi.org\/10.1111\/imj.14377.","journal-title":"Intern Med J"},{"key":"2062_CR24","doi-asserted-by":"publisher","first-page":"668481","DOI":"10.3389\/fonc.2021.668481","volume":"11","author":"M V\u00e1zquez","year":"2021","unstructured":"V\u00e1zquez M, Altabas M, Moreno DC, Geng AA, P\u00e9rez-Hoyos S, Giralt J. 30-day mortality following palliative radiotherapy. Front Oncol. 2021;11:668481. https:\/\/doi.org\/10.3389\/fonc.2021.668481.","journal-title":"Front Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02062-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-022-02062-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02062-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T11:16:29Z","timestamp":1652354189000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-022-02062-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2062"],"URL":"https:\/\/doi.org\/10.1186\/s13014-022-02062-x","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]},"assertion":[{"value":"21 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As a retrospective quality of care analysis, no approval from the Regional Committee for Medical and Health Research Ethics (REK Nord) was necessary. This research project was carried out according to our institutions\u2019 guidelines and with permission to access the patients' data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SGA has received lecture fees from Bristol Myer Squibb and Astra Zeneca. All other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}